← All trials
NCT07303660
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2026
- Primary completion
- Sep 30, 2026
- Completion date
- Nov 30, 2027
- First posted
- Dec 26, 2025
- Last posted
- Dec 26, 2025
- Enrollment
- 66
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lomond Therapeutics Holdings, Inc.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.